TEZEPELUMAB
Information current as at: 1 July 2026
PBAC meeting date: November 2026
Submission Details
- Brand name:
-
- Tezspire®
- Form and strength:
-
- Solution for injection 210 mg in 1.91 mL single dose pre-filled pen (110 mg per mL)
- Submission sponsor:
- ASTRAZENECA PTY LTD
- Condition/indication:
(therapeutic use) -
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Listing requested:
- To request listing of tezepelumab for the treatment of adult patients with severe CRSwNP who have received prior NP surgery (or are unsuitable for surgery) and remain inadequately controlled with intra-nasal corticosteroids (unless contraindicated or not tolerated).
- Funding program:
- PBS Section 100 (Highly Specialised Drugs Program)
- Request authority level:
- Authority Required (Written) for initial treatment Authority Required (STREAMLINED) for continuing treatment
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - November 2026 PBAC meeting
-
2Opportunity for consumer comment:
- Open 22/07/2026 and close 16/09/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
a1312
Page last updated
23 July 2026
v.9.19